The Hyperphosphatemia In Chronic Kidney Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hyperphosphatemia In Chronic Kidney Disease. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Hyperphosphatemia In Chronic Kidney Disease by nine companies/universities/institutes. The top development phase for Hyperphosphatemia In Chronic Kidney Disease is phase ii with four drugs in that stage. The Hyperphosphatemia In Chronic Kidney Disease pipeline has eight drugs in development by companies and one by universities/ institutes. Some of the companies in the Hyperphosphatemia In Chronic Kidney Disease pipeline products market are: Keryx Biopharmaceuticals, OPKO Health and Vidasym.

The key targets in the Hyperphosphatemia In Chronic Kidney Disease pipeline products market include Phosphate.

The key mechanisms of action in the Hyperphosphatemia In Chronic Kidney Disease pipeline product include Phosphate Binder with five drugs in Phase III. The Hyperphosphatemia In Chronic Kidney Disease pipeline products include one routes of administration with the top ROA being Oral and two key molecule types in the Hyperphosphatemia In Chronic Kidney Disease pipeline products market including Small Molecule, and Polymer.

Hyperphosphatemia In Chronic Kidney Disease overview

Hyperphosphatemia, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease (CKD). Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus, and rash. Treatment includes phosphate binders and diuretics.

For a complete picture of Hyperphosphatemia In Chronic Kidney Disease’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.